SRL
JANX icon

Scientech Research LLC’s Janux Therapeutics JANX Stock Holding History

Scientech Research LLC’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,174
Closed -$534K – 659
2024
Q1 		$534K Buy
+14,174
New +$309K 0.28% 127

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Scientech Research LLC's JANX Position: Q2 2024 in Review

Scientech Research LLC sold out of Janux Therapeutics (JANX) in Q2 2024, closing a stake of 14,174 shares — an estimated $534K sold.

Scientech Research LLC first reported a position in JANX in Q1 2024 and held it in 1 quarter. The position peaked at $534K in Q1 2024. 155 funds tracked by Wall St. Rank hold JANX as of Q2 2024.

  • Scientech Research LLC reported no remaining Janux Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Scientech Research LLC sold 14,174 Janux Therapeutics shares in Q2 2024, an estimated $534K.
  • Scientech Research LLC first reported a position in Janux Therapeutics in Q1 2024 and held it in 1 quarter.
  • Scientech Research LLC's Janux Therapeutics position peaked at $534K in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2024.

Based on Scientech Research LLC's 13F filing for Q2 2024, filed 14 Aug 2024.